Pedro Such

723 total citations
32 papers, 486 citations indexed

About

Pedro Such is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Philosophy. According to data from OpenAlex, Pedro Such has authored 32 papers receiving a total of 486 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Psychiatry and Mental health, 7 papers in Pediatrics, Perinatology and Child Health and 5 papers in Philosophy. Recurrent topics in Pedro Such's work include Schizophrenia research and treatment (23 papers), Bipolar Disorder and Treatment (16 papers) and Pharmaceutical studies and practices (7 papers). Pedro Such is often cited by papers focused on Schizophrenia research and treatment (23 papers), Bipolar Disorder and Treatment (16 papers) and Pharmaceutical studies and practices (7 papers). Pedro Such collaborates with scholars based in Denmark, United States and Spain. Pedro Such's co-authors include P. Hertel, Joan Amatniek, Joseph R. Calabrese, B. Johnson, Siegfried Kasper, William H. Carson, Eugenio Aguglia, Riccardo Torta, Pedro L. Delgado and Pamela Perry and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Affective Disorders and Movement Disorders.

In The Last Decade

Pedro Such

28 papers receiving 470 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pedro Such Denmark	11	307	135	73	64	59	32	486
Shubhra Mace United Kingdom	9	277 0.9×	125 0.9×	93 1.3×	49 0.8×	38 0.6×	14	467
Anna Sparshatt United Kingdom	13	405 1.3×	150 1.1×	77 1.1×	60 0.9×	55 0.9×	16	581
Philippe Bouhours France	11	329 1.1×	131 1.0×	70 1.0×	74 1.2×	46 0.8×	20	481
Raffaele Migliore United States	9	473 1.5×	112 0.8×	87 1.2×	60 0.9×	24 0.4×	13	541
Catherine Weiss Denmark	14	370 1.2×	273 2.0×	77 1.1×	86 1.3×	19 0.3×	40	502
Musa Sami United Kingdom	9	223 0.7×	285 2.1×	76 1.0×	37 0.6×	49 0.8×	24	461
Filippo Corponi Italy	12	254 0.8×	98 0.7×	107 1.5×	61 1.0×	41 0.7×	20	497
Cedric O’Gorman United States	13	450 1.5×	82 0.6×	107 1.5×	84 1.3×	18 0.3×	31	609
Ahsan Y. Khan United States	10	188 0.6×	154 1.1×	59 0.8×	124 1.9×	23 0.4×	25	467
Julie Cole United States	12	335 1.1×	97 0.7×	102 1.4×	70 1.1×	45 0.8×	17	611

Countries citing papers authored by Pedro Such

Since Specialization

Citations

This map shows the geographic impact of Pedro Such's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro Such with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro Such more than expected).

Fields of papers citing papers by Pedro Such

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro Such. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro Such. The network helps show where Pedro Such may publish in the future.

Co-authorship network of co-authors of Pedro Such

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro Such. A scholar is included among the top collaborators of Pedro Such based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro Such. Pedro Such is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cummings, Jeffrey L., Pedro Such, David Wang, et al.. (2025). Brexpiprazole for agitation in clinically relevant patient subgroups: a post hoc analysis of efficacy and safety in patients with agitation associated with dementia due to Alzheimer’s disease. Current Medical Research and Opinion. 41(8). 1523–1534. 1 indexed citations

Pappa, Sofia, et al.. (2025). Exploring Patient, Caregiver, and Prescriber Preferences for an Injectable Antipsychotic Administered Every 2 Months for the Maintenance Treatment of Schizophrenia: A Multicenter Qualitative Interview Study Conducted in Europe. Patient Preference and Adherence. Volume 19. 1179–1195. 1 indexed citations

Grossberg, George T., et al.. (2025). Efficacy of Brexpiprazole on Neuropsychiatric Symptoms and Impact on Caregivers: Pooled Neuropsychiatric Inventory (NPI) Analysis in Patients With Agitation Associated With Dementia due to Alzheimer’s Disease. Journal of Geriatric Psychiatry and Neurology. 386826516–386826516.

Shah, Alpesh, Pamela L. Sheridan, Dalei Chen, et al.. (2025). Safety and Tolerability of Brexpiprazole in Participants with Agitation Associated with Dementia due to Alzheimer’s Disease: Pooled Analysis of Three Randomized Trials and an Extension Trial. CNS Drugs. 39(10). 1011–1023. 2 indexed citations

Wang, David, et al.. (2024). Efficacy of brexpiprazole on agitation in patients with dementia due to Alzheimer’s disease exhibiting behaviors most bothersome to caregivers: post hoc pooled analysis of two randomized controlled trials. Alzheimer s & Dementia. 20(S3). e092333–e092333.

Such, Pedro, et al.. (2024). Use of an injection of aripiprazole given once every 2 months (Abilify Asimtufii^®) in people with bipolar I disorder: a Plain Language Summary of Publication. SHILAP Revista de lepidopterología. 14. 1957196142–1957196142.

Larsen, Frank, et al.. (2023). Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric Disease and Treatment. Volume 19. 1409–1416. 6 indexed citations

Such, Pedro, et al.. (2023). A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder. CNS Drugs. 37(4). 337–350. 17 indexed citations

McIntyre, Roger S., et al.. (2023). Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study. Current Medical Research and Opinion. 39(7). 1021–1030. 6 indexed citations

10.

Meyer‐Lindenberg, Andreas, Jacob Nielsen, Pedro Such, et al.. (2022). A double-blind, randomized, placebo-controlled proof of concept study of the efficacy and safety of Lu AF11167 for persistent negative symptoms in people with schizophrenia. European Neuropsychopharmacology. 61. 4–14. 9 indexed citations

11.

Kane, John M., Bruce J. Kinon, Carlos Forray, et al.. (2022). Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension. Schizophrenia Research. 248. 271–278. 10 indexed citations

12.

Crespo‐Facorro, Benedicto, et al.. (2020). The burden of disease in early schizophrenia – a systematic literature review. Current Medical Research and Opinion. 37(1). 109–121. 44 indexed citations

13.

Peters-Strickland, Timothy, et al.. (2019). <p>The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies</p>. Neuropsychiatric Disease and Treatment. Volume 15. 1659–1669. 5 indexed citations

14.

Such, Pedro, et al.. (2019). <p>Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment</p>. Neuropsychiatric Disease and Treatment. Volume 15. 2325–2338. 3 indexed citations

15.

Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2018). The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study. Journal of Affective Disorders. 241. 425–432. 15 indexed citations

16.

Calabrese, Joseph R., Na Jin, B. Johnson, et al.. (2018). Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. International Journal of Bipolar Disorders. 6(1). 14–14. 10 indexed citations

17.

Salzman, Phyllis, et al.. (2017). Plasma concentrations and dosing of 2 long-acting injectable formulations of aripiprazole. Neuropsychiatric Disease and Treatment. Volume 13. 1125–1129. 11 indexed citations

18.

Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2017). Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder. The Journal of Clinical Psychiatry. 78(3). 324–331. 72 indexed citations

19.

Calabrese, Joseph R., Raymond Sanchez, Na Jin, et al.. (2017). Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder. Journal of Affective Disorders. 227. 649–656. 21 indexed citations

20.

Hirschfeld, Robert M. A., Stuart Montgomery, Eugenio Aguglia, et al.. (2002). Partial Response and Nonresponse to Antidepressant Therapy. The Journal of Clinical Psychiatry. 63(9). 826–837. 148 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact